Total serious adverse events Duration: 1.75 to 3 years · patients with hypertension
First‐line thiazides showed no clear difference in total serious adverse events Duration: 1.75 to 3 years compared with first‐line calcium channel blockers (low certainty).
1 finding from 1 review
Number of participants with any serious adverse events · primary progressive multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Number of participants with any serious adverse events · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Grade 5 adverse events (excluding progressive disease) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
Next‐generation ALK inhibitor showed no clear difference in grade 5 adverse events (excluding progressive disease) compared with crizotinib (low certainty).
1 finding from 1 review
Grade 5 adverse events (excluding progressive disease) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor showed no clear difference in grade 5 adverse events (excluding progressive disease) compared with any cytotoxic chemotherapy (low certainty).
1 finding from 1 review
Average number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious thromboembolic events compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: serious thromboembolic events compared with chemotherapy (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse outcomes · atopic eczema
1 finding from 1 review
Maternal adverse events · women who have given birth vaginally, requiring analgesia for after‐birth pains.
It is very uncertain whether paracetamol changes maternal adverse events (up to 4 hours and at 6 hours) compared with placebo (very low certainty).
1 finding from 1 review
Maternal adverse events · women who have given birth vaginally, requiring analgesia for after‐birth pains.
It is very uncertain whether paracetamol changes maternal adverse events (up to 4 hours and at 6 hours) compared with NSAID (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse effects (number of people with adverse events) · people with postcraniotomy seizures
1 finding from 1 review
Adverse events in the child ‐ Congenital malformations · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
1 finding from 1 review
Adverse events in the child ‐ Congenital malformations · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
It is very uncertain whether aspirin changes adverse events in the child ‐ Congenital malformations compared with placebo (very low certainty).
1 finding from 1 review
Major adverse events · adults with renal and ureteral stones undergoing shock wave lithotripsy
1 finding from 1 review
Proportion of participants experiencing adverse events · Patients with acute low‐back pain
It is very uncertain whether NSAIDs changes proportion of participants experiencing adverse events compared with placebo (very low certainty).
1 finding from 1 review
Proportion of participants experiencing adverse events · Patients with acute low‐back pain
It is very uncertain whether selective COX‐2 inhibitors changes proportion of participants experiencing adverse events compared with non‐selective NSAIDs (very low certainty).
1 finding from 1 review
Adverse events: cotrimoxazole (1) versus cefprozil (2) · children with primarily normal renal tracts who have experienced at least one UTI
Antibiotic 1 showed no clear difference in adverse events: cotrimoxazole (1) versus cefprozil (2) compared with antibiotic 2 (low certainty).
1 finding from 1 review
Adverse events: clinically relevant (> 7%) weight gain · acute mania
Lithium showed no clear difference in adverse events: clinically relevant (> 7%) weight gain compared with aripiprazole (low certainty).
1 finding from 1 review
Number experiencing adverse effects · Patients with osteoarthritis of the knee or hip
Tramadol alone probably leads to higher number of participants experiencing any adverse events compared with placebo (moderate certainty).
1 finding from 1 review